As “funding lapse” for US FDA continues, agency continues to triage programs to maximize its ability to protect public health and safety. Is that laudable approach actually counterproductive?
It says something about the recent pattern of partisan disagreements in Washington, D.C. that FDA has developed a relatively robust playbook for how to handle a lapse in appropriations.
The first step is for everyone to report to work and execute an orderly shutdown. Managers write out plans for...
Recent studies show that spaceflight can significantly weaken astronauts’ immune systems, making them more susceptible to infections and health complications during and after missions. Understanding these changes is crucial for ensuring the safety of future long-duration space travelers.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
